Avid Bioservices, Inc. (CDMO): Price and Financial Metrics
Avid Bioservices, Inc. (CDMO)
Today's Latest Price: $6.30 USD
0.08 (-1.25%)
Updated Feb 28 4:00pm
Add CDMO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 215 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
CDMO Stock Summary
- The price/operating cash flow metric for Avid Bioservices Inc is higher than 94.57% of stocks in our set with a positive cash flow.
- With a year-over-year growth in debt of 25,313.98%, Avid Bioservices Inc's debt growth rate surpasses 99.58% of about US stocks.
- Revenue growth over the past 12 months for Avid Bioservices Inc comes in at 76.31%, a number that bests 92.66% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Avid Bioservices Inc, a group of peers worth examining would be RIBT, SITO, FI, RHI, and ETH.
- Visit CDMO's SEC page to see the company's official filings. To visit the company's web site, go to avidbio.com.
CDMO Daily Price Range
CDMO 52-Week Price Range
CDMO Stock Price Chart More Charts
CDMO Price/Volume Stats
| Current price | $6.30 | 52-week high | $8.38 |
| Prev. close | $6.38 | 52-week low | $3.37 |
| Day low | $6.04 | Volume | 480,100 |
| Day high | $6.36 | Avg. volume | 301,043 |
| 50-day MA | $6.91 | Dividend yield | N/A |
| 200-day MA | $5.82 | Market Cap | 354.93M |
Avid Bioservices, Inc. (CDMO) Company Bio
Avid Bioservices, Inc., formerly Peregrine Pharmaceuticals, researches and develops monoclonal antibodies for the treatment of cancer in the United States. Its lead immunotherapy candidate includes bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company was founded in 1981 and is based in Tustin, California.
Top Stories View All
How Low Will Stocks Go?
Best & Worst Performing Stock Industries for February 28, 2020
Best & Worst Performing Small Cap Stocks for February 28, 2020
Best & Worst Performing Mid Cap Stocks for February 28, 2020
Best & Worst Performing Large Cap Stocks for February 28, 2020
View All Top Stories
Loading social stream, please wait...